Bloomberg News

Exalenz Plunges Most in Five Months as Investment Talks End

By David Wainer
April 30, 2012

Exalenz Bioscience Ltd. (EXEN) plunged the most in five months in Tel Aviv trading after the maker of breath-testing systems ended talks to receive an investment from a private fund.

Exalenz tumbled 12 percent, the biggest intraday slump since Nov. 29, to 0.3520 shekel as of 3:58 p.m. in Tel Aviv, trimming its market value to 47 million shekels ($13 million).

To contact the reporter on this story: David Wainer in Tel Aviv at dwainer3@bloomberg.net

To contact the editor responsible for this story: Claudia Maedler at cmaedler@bloomberg.net

Business Exchange: What your peers are reading.

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

blog comments powered by Disqus